The future is now? Nuritas secures US$34m to accelerate healthcare solutions from AI and DNA analysis


03 Dec 2018 --- Irish biotech company Nuritas has secured a US$34m investment from the European Investment Bank (EIB) to increase and accelerate the development of artificial intelligence (AI) and DNA analysis to improve global healthcare. The investment follows Nuritas’ launch of PeptAIde earlier this year, in cooperation with BASF, which demonstrated how AI can accelerate the discovery of healthcare products. Future investment from EIB is to scale up development of new therapeutics in areas of interest including anti-aging, anti-inflammatory and diabetes treatment.

“Nuritas has already demonstrated through PeptAIde, their first product launch this year, how the discovery of healthcare products can be rapidly accelerated using artificial intelligence. During due diligence over recent months, the EIB has been impressed by their innovative use of technology and the number of global deals already achieved and they now become the first Irish biotech firm to benefit from the EIB’s dedicated European Growth Finance Facility,” says Andrew McDowell, EIB Vice President.

“Our goal is to find innovative and fast-growing companies so that we ensure they can benefit from access to long-term financing under the new initiative and Nuritas fits this bill perfectly. We look forward to working with other innovative and fast-growing companies to ensure they can benefit from access to long-term financing under the new initiative. This new 30 million euro support from the European Investment Bank will enable Nuritas to expand and commercialize even faster,” he adds.

Since starting operation in 2014, Nuritas has developed proprietary AI and DNA analysis to enhance the accurate analysis of molecules and peptides in food. The new technology is significantly faster with unparalleled accuracy compared to traditional methods of discovery, according to Nuritas.

The CEO of Nuritas, Emmet Browne, notes that the company is Ireland’s first biotech company to benefit from EIB investment, “which really delivers a potent signal of the regions desire to drive truly disruptive innovation.”

At the forefront of the AI and health intersection
Nuritas’ PeptAIde was launched last month, in collaboration with BASF, as a sports nutrition ingredient containing a unique set of plant-based peptides identified using AI, for regulating inflammation.

With industrial-scale production in Germany, PeptAIde is now available in the US, while commercialization is set to follow in the Asia Pacific and Europe by 2019. BASF was also seeking regulatory clearance to allow access to other key markets.

“Our research has shown that consumers today are seeking innovative, plant-based solutions to help them better manage sports-related inflammation,” says Tina Low, Vice President, Business Management BASF Human Nutrition. “PeptAIde’s unique properties will resonate very well with active consumers and enable our customers to take sports nutrition to the next level.”

The health and nutrition industry is increasingly looking toward technology to accelerate the discovery of health and nutrition solutions. Another example in this realm would be the recent acquisition by Medtronic, a provider of medical technology, of Nutrino Health, a provider of nutrition-related data services, analytics and technologies.

This acquisition seeks to boost diabetes management techniques and the companies reportedly see an opportunity to improve clinical outcomes for people with diabetes by integrating Nutrino's extensive food analysis infrastructure, nutrition science expertise and AI-driven personalized insights with Medtronic's technology and future innovations.

To contact our editorial team please email us at

Related Articles

Health & Nutrition News

On your feet: Gelita’s collagen peptide promotes the healing of tendons, study finds

21 Feb 2019 --- A specific bioactive collagen peptide may reduce pain and functional limitations in people suffering from Achilles tendon injury when combined with a rehabilitation program. This is according to a new study from the Australian Institute of Sport (AIS), published in Nutrients. The double-blind, placebo-controlled study used Tendoforte, Gelita’s recent addition to its Bioactive Collagen Peptides portfolio. As consumers continue to engage in a higher number of sporting activities, as well as more intense regimes, nutritional strategies to strengthen connective tissue are needed, notes Gelita.

Health & Nutrition News

“Far-reaching impact”: Plasma Nutrition’s io technology boosts whey's bioavailability, study confirms

20 Feb 2019 --- Plasma Nutrition’s Ingredient Optimized technology significantly improves the bioavailability of whey protein, according to a new study published in the Journal of Nutrition and Metabolic Insights. The findings note that the US start-up’s ioWhey protein improves the absorption of leucine, as well as that of branch chain amino acids (BCAAs) and essential amino acids (EAAs) in general. The study is the first publication on ioWhey protein and signals a “major breakthrough” for the start-up as it seeks “to pave the way in the advancement of nutrition science.”

Health & Nutrition News

Protein popcorn anyone? Breeding scheme and novel CRISPR-Cas9 method could spur high-protein cereals

20 Feb 2019 --- US researchers have successfully increased lysine levels in popcorn and sorghum by adopting different approaches – one being a traditional breeding scheme and the other, an emergent CRISPR-Cas9 method. The key amino acid lysine is typically scarce in many cereal grains and higher levels could, thus, add nutritional and economic value, broadening the appeal of grains. Boosting the protein profile of sorghum, which is a dietary staple in some developing parts of the world, could make the crop a more complete source of nutrition for people and livestock.


Microencapsulated Nutrient Fortification

19 Feb 2019 --- Vitamins and minerals encapsulated by fluid bed technology are suited for further processing.

Health & Nutrition News

“Applying the modern technology of AI to the ancient practice of food”: Nuritas exec

14 Feb 2019 --- Unlike traditional biotechs and academics that have searched for life’s panacea in exotic and rare places, Irish biotech company Nuritas is unlocking life-changing molecules in commonly consumed, everyday staple foods. This is according to Neil Foster, Head of Strategic Partnerships at Nuritas, who spoke to NutritionInsight on the company’s expanding partnership list and how it’s pushing the innovation boat further than ever before.

More Articles